Bridging drug discovery science and biotech operations
Cassia Life Sciences supports biotech, pharmaceutical and investor partners. We help with small molecule drug discovery, early development, outsourced R&D and strategic decision-making.
We bring senior experience across discovery science, operations and commercial strategy. As a result, we help our partners make clearer decisions and build stronger R&D plans.
Introduction
Cassia Life Sciences is a consultancy company based in Siena, Italy. We work with biotech companies, pharmaceutical organisations, investors and early-stage ventures.
We help clients shape, evaluate and progress small molecule discovery projects. In addition, we support outsourced R&D models, investor discussions and project planning.
Our expertise covers medicinal chemistry, DMPK, screening, compound management, CRO/CDMO oversight and diligence. Therefore, we can support both the science and the strategy behind early drug discovery.
Four service pillars
Drug discovery science
We support small molecule projects from hit finding to lead optimization. We also help clients prepare for preclinical development.
Our work includes medicinal chemistry strategy, data analysis and multiparameter optimization.
In addition, we review structure-activity and structure-property relationships, synthetic strategy and developability risks.
R&D operations and outsourcing
Many discovery projects rely on external partners. Therefore, effective CRO and CDMO management is essential.
Cassia can help clients select, onboard and manage outsourced resources.
We also support project governance, data review and operational troubleshooting.
Strategic support for biotechs
Strong discovery projects need clear scientific and commercial logic.
As a result, we help clients prepare for investor discussions, diligence and strategic decisions.
Our support can include pitch deck review, research plan costing, project setup, portfolio input and fractional leadership.
Investor diligence and review
Investors & incubators need independent input before committing resources.
Therefore, Cassia supports scientific and commercial diligence for VCs and incubators evaluating startup investments, as well as private equity firms considering M&A opportunities in life sciences service companies.
We assess scientific rationale, novelty, feasibility, competitive positioning, operational quality and key development risks. In addition, we help identify the strengths, weaknesses and decision points that matter before investment or acquisition.
Why Cassia
Cassia combines scientific depth with practical biotech experience. We have worked across multiple therapeutic areas, including neuroscience, oncology and anti-infectives.
Early discovery brings scientific, operational and commercial challenges. Moving projects forward also requires clear decisions on resources, priorities and execution.
Because of this, we focus on clear advice, realistic plans and decision-ready recommendations.
Let’s discuss your discovery challenge
Whether you are shaping a new discovery programme, reviewing an existing asset or preparing for investor discussions, Cassia can help.
Cassia provides experienced, independent support tailored to your project stage and business needs.